/
Musculoskeletal
Ankylosing Spondylitis
18
Pipeline Programs↗
14
Active Trials↗
30
Companies Involved↗
Ankylosing Spondylitis is an emerging landscape with 18 programs across 30 companies. The most active players are Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Jiangsu vcare pharmaceutical technology co., LTD, Lynk Pharmaceuticals Co., Ltd. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 1
No programs
Phase 2
No programs
Phase 33
Approved
No programs
Analysis
Trial Status
179
clinical trials
Completed125 · 70%
Unknown status24 · 13%
Terminated11 · 6%
Recruiting7 · 4%
Withdrawn5 · 3%
Active, not recruiting4 · 2%
Other3 · 2%
Clinical Trials
Trial Activity
179 trials
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
Not yet recruiting·TThe Affiliated Hospital Of Guizhou Medical University·Phase 4·NCT06833112·10 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)